Levels of CD38 and/or myeloid-associated marker expression over the course of disease in 3 B-CLL patients
| Case #1 | |||
| Month* | 178 | 182† | 203 |
| CD38 level | 20% | 38%† | 57% |
| Case #2 | |||
| Month | 93 | 94 | 96† |
| CD13 level | 2% | 0% | 50%† |
| Case 3 | |||
| Month | 136 | 147† | NA |
| CD38 level | 21% | 48%† | NA |
| CD15 level | 13% | 38%† | NA |
| Case #1 | |||
| Month* | 178 | 182† | 203 |
| CD38 level | 20% | 38%† | 57% |
| Case #2 | |||
| Month | 93 | 94 | 96† |
| CD13 level | 2% | 0% | 50%† |
| Case 3 | |||
| Month | 136 | 147† | NA |
| CD38 level | 21% | 48%† | NA |
| CD15 level | 13% | 38%† | NA |